Did Jim Cramer Nail or Miss These 11 Stock Predictions?

6. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 19

In that older episode, a caller brought up Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), highlighting a recent announcement and its link to Nvidia. Cramer backed the speculative play:

“They do have an investment — and it’s a serious investment — by Nvidia in them. I think, therefore, it’s a terrific spec, and I would buy it.”

Cramer’s speculative enthusiasm didn’t work out as the stock dropped 54.82%. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) uses machine learning to accelerate drug discovery, integrating high-throughput biology with AI-driven insights.

Jim Cramer remains hopeful for the biotech company. He even gave a bullish thesis for the stock in April:

“Alright, we got some news from the FDA that’s impacting the stock. I don’t normally do small caps, but there’s an FDA announcement, plan to phase out animal testing requirements for monoclonal antibodies. By the way, Regeneron, biggest in that. But what they’re gonna do is you gotta do it AI. And the AI company that has it, I’ve had them on, is Recursion Pharmaceuticals, RxRx, backed by Jensen Huang and NVIDIA. And they’re going to be the winner in how we decide much faster to have drugs approved in this country. It’s the first real deregulation I’ve seen. Congratulations to the people who are trying to deregulate.”